14 results about "Striatum" patented technology

Described herein, inter alia, are compositions and methods of use for administering a population of regulatory T (TREG) cells and / or a population of midbrain dopamine (mDA) cells to the brain of a subject (e.g., treating Parkinson's disease and / or reducing immune responses due to acupuncture wounds during cell transplantation).

The invention discloses application of C-176 in preparation of a medicine for treating Parkinson's disease, belongs to the technical field of medicines, and particularly relates to a medicine for treating Parkinson's disease, which comprises C-176 or a pharmaceutical salt thereof. As an STING inhibitor C-176 is adopted as a medicine for treating Parkinson's disease, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) is utilized to construct an animal model of Parkinson's disease, and animal experiments prove that the expression of STING protein in striatum of a mouse in the model is increased, and the expression of tyrosine hydroxylase (TH) is reduced at the same time. The C-176 can improve the expression level of TH in striatum of a Parkinson model mouse. A behavioral experiment result proves that the C-176 can improve the movement and movement coordination ability of a model mouse and relieve the anxiety behavior of the model mouse.

The present invention relates to a method for treating autism spectrum disorder, a mouse for monitoring autism spectrum disorder, and a method for screening a candidate for preventing or treating autism spectrum disorder. Specifically, according to the present invention, the output signal (or excitation of population) of neurons of the ventrolateral thalamus (VL), the laterodorsal thalamus (LD) or the striatum may be suppressed by introducing a halorhodopsin protein into neurons of the ventrolateral thalamus (VL), the laterodorsal thalamus (LD) or the striatum and then irradiating light to induce hyperpolarization of the halorhodopsin protein. Thus, the present invention has the effect of preventing or treating autism.

Provided herein are novel methods for delivering recombinant adeno-associated viral (rAAV) particles to the central nervous system of a mammal (e.g., a human). In aspects, the methods involve administering rAAV particles containing a heterologous nucleic acid to the striatum and causing expression of the heterologous nucleic acid in at least the cerebral cortex and the striatum of the mammal.

To provide anti-DAT antibodies and compositions thereof for slowing the progression of Parkinson's disease.SOLUTION: Anti-DAT antibodies are formed by transcription and translation of gene fragments containing specific sequences. The anti-DAT antibody provided by the present invention is used for labeling a dopamine transporter. The anti-DAT antibody provided by the present invention is capable of forming a composition that crosses the blood-brain barrier, is capable of specifically binding to dopaminergic neurons, and is capable of specifically binding to cells in the striatum The use of reducing the deposition of α - synuclein protein in the brain region is achieved, and the excellent effect of delaying the progress of Parkinson's disease is exerted.SELECTED DRAWING: Figure 1

The invention relates to an application of bifidobacterium animalis subsp. Lactis BLa80 in preparation of a preparation for improving Parkinson's disease. The bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.22547, and the strain of the bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC No.22547. The brand new application of the BLa80 strain of the animal bifidobacterium subsp. Lactis is developed, namely the BLa80 strain is used for improving the Parkinson's disease, specifically, the BLa80 strain can weaken the cytotoxicity of 6-OHDA induced SH-SY5Y cells, relieve weight loss of MPTP induced subacute Parkinson's disease model mice, relieve dyskinesia of the mice and improve the Parkinson's disease. According to the present invention, the mice are subjected to the mouse striatum activation, such that the dopaminergic neuron is protected, the dopamine content in the mouse striatum is increased, the intestinal inflammation is relieved, the ratio of the thick-wall mycophylum to the bacteroides in the mouse intestinal flora is increased, the intestinal beneficial flora abundance is improved, and the intestinal flora diversity is increased;

Diagnosing and treating presbycusis (age related hearing loss) includes measuring basilar membrane stiffness. In an example, a low frequency component of an electrocochleogram stimulation signal is used to bias a region of the basilar membrane, the results of which are used basilar membrane stiffness. The resulting measurement is used to measure a subcomponent of presbycusis. Further, the measurement can be combined with known diagnostic methods to reveal or distinguish other origins of hearing loss such as strial presbycusis, sensory presbycusis, neural presbycusis, and cochlea conductive presbycusis. The relative contributions for each of the diagnosed origins of hearing loss can be determined.

The invention discloses application of Trolox in preparation of a medicine for treating neurodevelopment disorder related diseases, and belongs to the technical field of biological medicine. The invention firstly discovers that Trolox has new application of drugs for preventing and / or treating neurodevelopment disorder related diseases; furthermore, the Trolox restores the neural connectivity by repairing the densities of the damaged neuron dendritic spines of the brain hippocampus and / or striatum; abnormal dopaminergic signal channels are corrected, so that expression of key receptors and downstream molecules thereof is recovered to be normal, and therefore, diseases related to neurodevelopment disorders are prevented and / or treated; the neuroprotective effect of Trolox depends on the activation of dopamine D1 and D2 receptor pathways; in addition, the invention discloses the potential of Trolox in the aspect of targeted repair of the core pathology link of the neurodevelopmental disorder for the first time, and a clear candidate compound and an action target are provided for developing a novel medicine for treating the diseases.

This invention relates to the field of pharmaceutical technology for treating motor dysfunction in Parkinson's disease, and particularly to a traditional Chinese medicine preparation for treating motor dysfunction in Parkinson's disease. The formula consists of Cimicifuga rhizome, processed turtle shell, Angelica sinensis, raw licorice root, ginger-processed Pinellia ternata, Gastrodia elata, and scorpion. This invention uses a traditional Chinese medicine formula to treat motor dysfunction in Parkinson's disease. The medicinal materials comply with national regulations for the management of traditional Chinese medicine materials and have undergone clinical testing. The formula is rationally formulated with high synergistic effects and long-lasting and stable efficacy. Based on the principles of traditional Chinese medicine syndrome differentiation and treatment, this formula addresses the deficiency of both liver and kidney, and the insufficiency of qi and blood, with tremor and paralysis attributed to internal liver wind. It significantly improves motor dysfunction and tremor symptoms in Parkinson's disease. This preparation is highly effective, safe, reliable, and has few side effects. It can also significantly reduce the expression levels of tyrosine hydroxylase in the substantia nigra and striatum. This preparation represents a new approach to treating motor dysfunction in Parkinson's disease and has broad prospects in the field of treating this condition.

The invention provides a transcranial magnetoacoustic stimulation system based on regulation and control of a cortical-basal node neural circuit. The transcranial magnetoacoustic stimulation system comprises a digital signal generator, a radio frequency power amplifier, an ultrasonic transducer, an oscilloscope, a microelectrode array and two permanent magnets, the digital signal generator is connected with the ultrasonic transducer through the radio frequency power amplifier, and the ultrasonic transducer is provided with a collimator and emits ultrasonic waves in a pulse form; the microelectrode array is arranged on the head of a stimulated object and is used for collecting electroencephalogram signals in real time when stimulation is executed; the permanent magnets are fixed to the two sides of the head of a stimulated object, static magnetic fields and focused ultrasonic stimulation are applied to a target brain area at the same time, and neural activities of the deep brain area are regulated and controlled through the magnetoacoustic coupling effect. According to the application, the magnetoacoustic coupling effect is utilized to perform non-invasive regulation and control on neural activity in the deep brain region, so that the neural oscillation synchronism between the prefrontal lobe and the striatum is enhanced, and the motor and cognitive dysfunction related to the Parkinson's disease is improved.

The invention relates to the technical field of disease model construction, in particular to a construction method of a vascular Parkinson's syndrome composite animal model. The method comprises the following steps: sequentially performing chronic whole-brain hypoperfusion treatment and systemic mitochondrial complex I inhibition treatment on an advanced mammal, and applying the vascular Parkinson's syndrome animal model to preparation of a medicine for screening or evaluating prevention and / or treatment of the vascular Parkinson's syndrome. According to the construction method of the vascular Parkinson's syndrome composite animal model provided by the invention, a stable cerebrovascular lesion and a definite nigra-strike dopamine energy system are simultaneously induced on the same animal individual through an innovative double-strike modeling method; therefore, a brand-new animal model which is highly similar to human diseases in pathology is created.

This invention relates to a self-microemulsion formulation of Vietnamese camellia seed oil, a self-microemulsion formulation of piperine using Vietnamese camellia seed oil as the oil phase, and their preparation methods and applications. This invention prepares the optimal formulation of the Vietnamese camellia seed oil self-microemulsion formulation and the piperine self-microemulsion formulation using Vietnamese camellia seed oil as the oil phase through formulation screening and optimization. In vitro cell experiments and in vivo pharmacodynamic experiments show that the Vietnamese camellia seed oil self-microemulsion formulation has neuroprotective activity, can alleviate neuronal damage in the brain regions of Parkinson's disease model rats, can also improve motor dysfunction in Parkinson's disease model rats, and upregulate the levels of DA, DOPAC, and HVA in the striatum of the injured side of the Parkinson's disease model rats. Furthermore, when used in combination with piperine, it enhances the ameliorative effect of piperine on Parkinson's disease, exhibiting a good synergistic effect and providing a new treatment method for Parkinson's disease.

An anti-DAT antibody which is formed from a gene comprising SEQ ID No:2 after transcription and translation. The anti-DAT antibody of the present invention can be made into a composition capable of crossing the blood-brain barrier, and specifically binding to dopamine nerve cells, and achieving excellent efficacy in reducing the accumulation of α-syn in the striatum and delaying the course of Parkinson's disease.

The present invention relates to the use of a combination of two or more of a D2 agonist, an adenosine A2A receptor antagonist, a histamine H3 antagonist or inverse agonist, a mGluR5 receptor antagonist, or a nicotinic α4-β2 and / or α7 receptor agonist to increase D2 dopaminergic molecular signaling in the striatum for the treatment of psychiatric or neurological disorders in which anhedonia or motivation-related dysfunction exists (such as major depressive disorder, bipolar I or II disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative symptoms) and Parkinson's disease (e.g. non-motor features such as depression and apathy)).